Minimally invasive rectal cancer surgery after neoadjuvant therapy in selected elderly and frail patients: A single-center real-world experience

Table 4 Survival outcomes: Overall survival, cancer-specific survival, and disease-free survival stratified by age and frailty

Outcome	Variable	Median (months)	IQR/CI	Log-rank P value	HR univariable (95%CI)	P value	HR multivariable (95%CI)	P value
Overall survival	Age ≥ 80 years	47	29-NR	0.021	Ref		Ref
	Age < 80 years	NR			0.41 (0.19-0.89)	0.025	0.44 (0.20-0.98)	0.044
	Frail	32	22-NR	0.058	Ref		Ref
	Non-frail	NR			0.43 (0.17-1.06)	0.066	0.48 (0.19-1.22)	0.124
	Age ≥ 80 + frail	20	9
	Age ≥ 80 + non-frail	26.5	34.5
	Age < 80 + frail	32	13
	Age < 80 + non-frail	33.5	34.0
Cancer-specific survival	Age ≥ 80	26	18-47	0.14	Ref		Ref
	Age < 80	32	26-38		0.42 (0.18-0.96)	0.040	0.43 (0.19-1.00)	0.051
	Frail	NR		0.38	Ref		Ref
	Non-frail	NR			0.62 (0.21-1.82)	0.384	0.71 (0.24-2.12)	0.541
Disease-free survival	Age ≥ 80	NR	≥ 31	0.53	Ref
	Age < 80	NR	≥ 69		1.40 (0.49-4.00)	0.527
	Frail	NR	≥ 13	0.10	Ref
	Non-frail	NR	≥ 69		0.48 (0.20-1.18)	0.110

IQR: Interquartile range; HR: Hazard ratio; CI: Confidence interval; NR: Not reached; Ref: References.